2. Search Result
Search Result
Results for "

FOXM1

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Peptides

1

Natural
Products

1

Recombinant Proteins

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151986
    FOXM1-IN-1

    		Others Cancer
    FOXM1-IN-1 is a potent FOXM1 inhibitor with an IC50 value of 2.65 µM. FOXM1-IN-1 shows antiproliferative activity. FOXM1-IN-1 decreases the the expression of FOXM1, PLK1, CDC25B protein [1].
    FOXM1-IN-1
  • HY-112721
    FDI-6
    2 Publications Verification

    		 Others Cancer
    FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.
    FDI-6
  • HY-B0990
    Thiostrepton
    Maximum Cited Publications
    16 Publications Verification

    		 Bacterial Antibiotic Infection
    Thiostrepton is a thiazole antibiotic which selectively inhibits FOXM1. FOXM1 binds to YAP/TEAD complex. YAP/TEAD/FOXM1 complex binding at regulatory regions of genes governing cell cycle may impact cell proliferation [1].
    Thiostrepton
  • HY-19979
    RCM-1
    2 Publications Verification

    		 Others Cancer
    RCM-1 is a forkhead box M1 (FOXM1) inhibitor with an EC50 of 0.72 μM in U2OS cells. RCM-1 blocks the nuclear localization and increased the proteasomal degradation of FOXM1. RCM-1 can be used for asthma and other chronic airway diseases research [1].
    RCM-1
  • HY-117522
    Sepin-1

    		Separase Cancer
    Sepin-1 is a potent separase inhibitor with an IC50 value of 14.8 µM. Sepin-1 inhibits cell proliferation, migration and wound healing. Sepin-1 decreases the expression of FoxM1 protein and mRNA level. Sepin-1 shows anti-tumor activity [1] .
    Sepin-1
  • HY-148530
    YX-2-107

    		PROTACs CDK Cancer
    YX-2-107 is a PROTAC (IC50= 4.4 nM) that selectively degrades CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph + ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph +) acute lymphoblastic leukemia (ALL) [1].
    YX-2-107
  • HY-RS05064
    FOXM1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    FOXM1 Human Pre-designed siRNA Set A contains three designed siRNAs for FOXM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FOXM1 Human Pre-designed siRNA Set A
    FOXM1 Human Pre-designed siRNA Set A
  • HY-156609
    FOXM1-IN-2

    		Others Cancer
    FOXM1-IN-2 is a FOXM1 inhibitor, with antineoplastic activity [1].
    FOXM1-IN-2
  • HY-158420
    STL001

    		Autophagy Cancer
    STL001 is potent and selective FOXM1 inhibitor. STL001 induces the translocation of nuclear FOXM1 to the cytoplasm and promotes its autophagic degradation. STL001 sensitizes human cancers to a broad-spectrum of cancer therapies [1].
    STL001
  • HY-P1687
    Siomycin A

    		Bacterial Apoptosis Cancer
    Siomycin A is a thiopeptide antibiotic and is a Forkhead box M1(FOXM1) selective inhibitor without affecting other members of the Forkhead box family. Siomycin A has anti-tumor and promotes apoptosis [1] .
    Siomycin A
  • HY-112509
    STL427944

    		Autophagy Cancer
    STL427944 is a potent and selective FOXM1 inhibitor. STL427944 has the potential for the research of overcoming tumor chemoresistance and improving the efficacy of treatment with conventional cancer drug [1].
    STL427944
  • HY-161617
    LASSBio-2052

    		Others Cancer
    LASSBio-2052 is a derivative of N-acylhydrazone with antitumor activity against hepatocellular carcinoma (HCC). LASSBio-2052 inhibits HCC cells HepG2 and Hep3B, with IC50 of 18 and 41 μM. LASSBio-2052 arrests the cell cycle at G2/M phase, through downregulation of FOXM1. LASSBio-2052 induces apoptosis in HCC cells [1].
    LASSBio-2052
  • HY-P10553
    ARF(26–44), cell-permeable

    		Apoptosis Cancer
    ARF(26–44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable can be used in research on tumor therapy [1].
    ARF(26–44), cell-permeable

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: